Serina Therapeutics Inc (SER)

AMEXHealth CareBiotechnologySnapshot 2026-10-23

$1.65-6.25%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Serina Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.3
Annual ending 2026-12-31
Revenue	—	0
EPS	—	-1.579
Annual ending 2027-12-31
Revenue	—	0
EPS	—	-1.153

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
resolve NYSE American minimum stockholders' equity non-compliance	The company is working to fix NYSE compliance and improve finances.	Improving	NYSE compliance issues remain unresolved past FY26	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
reduce net losses and improve operating income	A primary condition in Serina Therapeutics Inc's published investment case. The stated target is net loss narrows from -$6.9M in 2026-Q1 to less than -$3M by FY26 end.	Improving	net loss remains at or worsens beyond -$6.9M by FY26 end	Net income: $-6.356M FY2026-Q2; GAAP. Published target: net loss narrows from -$6.9M in 2026-Q1 to less than -$3M by FY26 end. Target period is not explicitly aligned with this observation. Source published Aug 13, 2026-6,356,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: db9f4ddf-4326-41bd-94c6-1c98229d4841. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
raise capital to support operations and pipeline development	A supporting condition in Serina Therapeutics Inc's published investment case. The stated target is successful capital raises sufficient to fund operations through FY26.	Intact	no material funding secured by end of FY26	Material funding secured (Aug 2026) vs target by FY26 August 2026 8-K confirms entry into a Material Definitive Agreement for capital raise with Roth Principal Investments. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 0
2026-07-25	Unavailable	Unavailable	1 / 0
2026-07-26	Unavailable	Unavailable	1 / 0
2026-07-27	Unavailable	Unavailable	1 / 0
2026-07-28	Unavailable	Unavailable	1 / 2
2026-07-29	Unavailable	Unavailable	1 / 0
2026-07-30	Unavailable	Unavailable	1 / 2
2026-07-31	Unavailable	Unavailable	1 / 0
2026-08-01	Unavailable	Unavailable	1 / 0
2026-08-02	Unavailable	Unavailable	1 / 2
2026-08-03	Unavailable	Unavailable	1 / 2
2026-08-04	Unavailable	Unavailable	1 / 0
2026-08-05	Unavailable	Unavailable	1 / 2
2026-08-06	Unavailable	Unavailable	1 / 2
2026-08-08	Unavailable	Unavailable	1 / 2
2026-08-09	Unavailable	Unavailable	1 / 2
2026-08-10	Unavailable	Unavailable	1 / 2
2026-08-12	Unavailable	Unavailable	1 / 0
2026-08-13	Unavailable	Unavailable	1 / 0
2026-08-14	Unavailable	Unavailable	1 / 0
2026-08-15	Unavailable	Unavailable	1 / 0
2026-08-16	Unavailable	Unavailable	1 / 0
2026-08-17	Unavailable	Unavailable	1 / 0
2026-08-18	Unavailable	Unavailable	1 / 0
2026-08-19	Unavailable	Unavailable	1 / 0
2026-08-20	Unavailable	Unavailable	1 / 0
2026-08-21	Unavailable	Unavailable	1 / 0
2026-08-22	Unavailable	Unavailable	1 / 0
2026-08-23	Unavailable	Unavailable	1 / 0
2026-08-24	Unavailable	Unavailable	1 / 0
2026-08-25	Unavailable	Unavailable	1 / 0
2026-08-26	Unavailable	Unavailable	1 / 0
2026-08-27	Unavailable	Unavailable	1 / 0
2026-08-28	Unavailable	Unavailable	1 / 0
2026-08-29	Unavailable	Unavailable	1 / 0
2026-08-30	Unavailable	Unavailable	1 / 0
2026-08-31	Unavailable	Unavailable	1 / 0
2026-09-01	Unavailable	Unavailable	1 / 0
2026-09-02	Unavailable	Unavailable	1 / 0
2026-09-03	Unavailable	Unavailable	1 / 0
2026-09-04	Unavailable	Unavailable	1 / 0
2026-09-05	Unavailable	Unavailable	1 / 0
2026-09-06	Unavailable	Unavailable	1 / 0
2026-09-07	Unavailable	Unavailable	1 / 0
2026-09-08	Unavailable	Unavailable	1 / 0
2026-09-09	Unavailable	Unavailable	1 / 0
2026-09-10	Unavailable	Unavailable	1 / 0
2026-09-11	Unavailable	Unavailable	1 / 0
2026-09-12	Unavailable	Unavailable	1 / 0
2026-09-13	Unavailable	Unavailable	1 / 0
2026-09-14	Unavailable	Unavailable	1 / 0
2026-09-15	Unavailable	Unavailable	1 / 0
2026-09-16	Unavailable	Unavailable	1 / 0
2026-09-17	Unavailable	Unavailable	1 / 0
2026-09-18	Unavailable	Unavailable	1 / 0
2026-09-19	Unavailable	Unavailable	1 / 0
2026-09-20	Unavailable	Unavailable	1 / 0
2026-09-21	Unavailable	Unavailable	1 / 0
2026-09-22	Unavailable	Unavailable	1 / 0
2026-09-23	Unavailable	Unavailable	1 / 0
2026-09-24	Unavailable	Unavailable	1 / 0
2026-09-25	Unavailable	Unavailable	2 / 0
2026-09-26	Unavailable	Unavailable	2 / 0
2026-09-27	Unavailable	Unavailable	2 / 0
2026-09-28	Unavailable	Unavailable	2 / 0
2026-09-29	Unavailable	Unavailable	2 / 0
2026-09-30	Unavailable	Unavailable	2 / 0
2026-10-01	Unavailable	Unavailable	2 / 0
2026-10-02	Unavailable	Unavailable	2 / 0
2026-10-03	Unavailable	Unavailable	2 / 0
2026-10-04	Unavailable	Unavailable	2 / 0
2026-10-05	Unavailable	Unavailable	2 / 0
2026-10-06	Unavailable	Unavailable	2 / 0
2026-10-07	Unavailable	Unavailable	2 / 0
2026-10-08	Unavailable	Unavailable	2 / 0
2026-10-09	Unavailable	Unavailable	2 / 0
2026-10-10	Unavailable	Unavailable	2 / 0
2026-10-11	Unavailable	Unavailable	2 / 0
2026-10-12	Unavailable	Unavailable	2 / 0
2026-10-13	Unavailable	Unavailable	2 / 0
2026-10-14	Unavailable	Unavailable	2 / 0
2026-10-15	Unavailable	Unavailable	2 / 0
2026-10-16	Unavailable	Unavailable	2 / 0
2026-10-17	Unavailable	Unavailable	2 / 0
2026-10-18	Unavailable	Unavailable	2 / 0
2026-10-19	Unavailable	Unavailable	2 / 0
2026-10-20	Unavailable	Unavailable	2 / 0
2026-10-21	Unavailable	Unavailable	2 / 0
2026-10-22	Unavailable	Unavailable	2 / 0
2026-10-23	Unavailable	Unavailable	2 / 0
2026-10-24	Unavailable	Unavailable	2 / 0

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	1	0	0
2026-06-01	1	0	0
2026-07-01	2	0	0
2026-08-01	2	0	0
2026-09-01	2	0	0
2026-10-01	2	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

resolve NYSE American minimum stockholders' equity non-complianceQualitative condition
reduce net losses and improve operating incomeNet income: $-6.356M

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.8%Typical daily move · historical

Downside history

-75.7%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Serina Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-stage growth, not an established earnings compounder. The multi-year view is on watch: SER has advanced its clinical work and strengthened its cash position, while recent performance remains weak and management execution is volatile.

What's priced into Serina Therapeutics Inc

The valuation model suggests SER trades at a premium to peers, with optionality as the main source of valuation divergence. Its priced-in tag is justified and fragility is low, but model confidence is low and the expectations gap is negative, so the valuation signal is uncertain.

What the fundamentals likely do

Near term, the elevated risk of an earnings miss and the recent earnings miss point to continued uncertainty. Operating expenses and net loss rose from the first to the second quarter of 2026, while cash remained strong; enrollment and dosing in Cohort 1 finished ahead of guidance, and the study advanced to Cohort 2. Top-line data are planned for H1 2027, so clinical progress matters more to the multi-year thesis than near-term earnings.

What Serina Therapeutics Inc hinges on

The key company-level test is whether SER continues advancing SER-252 and delivers the planned data, while keeping enough financial support for development. A guidance cut would add pressure, and a weaker jobs trend could weigh on cyclical names; continued strength from major Healthcare companies could support sector momentum. The evidence on the announced agreement and capital-allocation event is limited, so their effect on the thesis is unclear.